{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["60"],"submitter":["Cham S"],"pubmed_abstract":["<h4>Purpose</h4>Uterine carcinosarcoma (UCS) is a rare but aggressive tumor with high rates of recurrence and poor prognosis, and novel therapies are urgently needed. P53 mutations are identified in over 90% of cases, and other cell cycle alterations are commonly found indicating potential vulnerability to Wee1 kinase inhibition. The purpose of this study was to determine the activity and safety of adavosertib, a Wee1 inhibitor, in recurrent or persistent UCS.<h4>Patients and methods</h4>This was a phase II single-institution study of patients with persistent or recurrent UCS. Eligible patients had a confirmed <i>TP53</i> alteration, RECIST measurable disease, and prior treatment with platinum based systemic therapy. Patients were treated with adavosertib at a starting dose of 300 mg orall"],"journal":["Gynecologic oncology reports"],"pagination":["101796"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12269869"],"repository":["biostudies-literature"],"pubmed_title":["Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma."],"pmcid":["PMC12269869"],"pubmed_authors":["Sawyer H","Tayob N","Matulonis UA","Xiong N","Mathews C","Lee EK","Konstantinopoulos PA","Liu JF","Krasner C","Wright AA","Cham S"],"additional_accession":[]},"is_claimable":false,"name":"Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma.","description":"<h4>Purpose</h4>Uterine carcinosarcoma (UCS) is a rare but aggressive tumor with high rates of recurrence and poor prognosis, and novel therapies are urgently needed. P53 mutations are identified in over 90% of cases, and other cell cycle alterations are commonly found indicating potential vulnerability to Wee1 kinase inhibition. The purpose of this study was to determine the activity and safety of adavosertib, a Wee1 inhibitor, in recurrent or persistent UCS.<h4>Patients and methods</h4>This was a phase II single-institution study of patients with persistent or recurrent UCS. Eligible patients had a confirmed <i>TP53</i> alteration, RECIST measurable disease, and prior treatment with platinum based systemic therapy. Patients were treated with adavosertib at a starting dose of 300 mg orall","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-03-27T15:50:36.159Z","creation":"2025-08-27T03:06:59.038Z"},"accession":"S-EPMC12269869","cross_references":{"pubmed":["40678577"],"doi":["10.1016/j.gore.2025.101796"]}}